Patient Characteristics
| . | Cirrhosis Cases (n = 31) . | Controls (n = 31) . |
|---|---|---|
| Age at transplant* (yrs) | ||
| Median | 30 | 28 |
| Range | 2.5-56 | 2.5-54 |
| Sex (M:F) | 14:17 | 12:19 |
| Years since first marrow transplant* (yrs) | ||
| Median | 15 | 16 |
| Range | 5-25 | 5-27 |
| Primary disease* | ||
| Hematologic malignancy | 24 | 24 |
| Chronic myelogenous leukemia | 9 | 9 |
| Acute myelogenous leukemia | 8 | 8 |
| Acute lymphocytic leukemia | 3 | 2 |
| Myelodysplastic syndrome | 1 | 1 |
| Lymphoma | 3 | 4 |
| Aplastic anemia | 7 | 7 |
| Donor type* | ||
| Allogeneic | 27 | 28 |
| HLA-matched related | 22 | 26 |
| HLA-mismatched related | 3 | 1 |
| HLA-matched unrelated | 2 | 1 |
| Syngeneic | 2 | 1 |
| Autologous | 2 | 2 |
| Conditioning regimen | ||
| TBI containing | 17 | 20 |
| Cyclophosphamide + TBI ± other drugs | 16 | 19 |
| Other TBI regimen | 1 | 1 |
| Non-TBI containing | 14 | 11 |
| Cyclophosphamide alone | 5 | 7 |
| Busulfan + cyclophosphamide | 5 | 3 |
| Anti-thymocyte globulin | 2 | 0 |
| None | 1† | 0 |
| Other | 1 | 1 |
| GVHD prophylaxis | ||
| Methotrexate only | 8 | 14 |
| Methotrexate + cyclosporine | 8 | 9 |
| Cyclosporine ± prednisone | 6 | 3 |
| Other regimens | 2 | 2 |
| None | 7‡ | 3 |
| . | Cirrhosis Cases (n = 31) . | Controls (n = 31) . |
|---|---|---|
| Age at transplant* (yrs) | ||
| Median | 30 | 28 |
| Range | 2.5-56 | 2.5-54 |
| Sex (M:F) | 14:17 | 12:19 |
| Years since first marrow transplant* (yrs) | ||
| Median | 15 | 16 |
| Range | 5-25 | 5-27 |
| Primary disease* | ||
| Hematologic malignancy | 24 | 24 |
| Chronic myelogenous leukemia | 9 | 9 |
| Acute myelogenous leukemia | 8 | 8 |
| Acute lymphocytic leukemia | 3 | 2 |
| Myelodysplastic syndrome | 1 | 1 |
| Lymphoma | 3 | 4 |
| Aplastic anemia | 7 | 7 |
| Donor type* | ||
| Allogeneic | 27 | 28 |
| HLA-matched related | 22 | 26 |
| HLA-mismatched related | 3 | 1 |
| HLA-matched unrelated | 2 | 1 |
| Syngeneic | 2 | 1 |
| Autologous | 2 | 2 |
| Conditioning regimen | ||
| TBI containing | 17 | 20 |
| Cyclophosphamide + TBI ± other drugs | 16 | 19 |
| Other TBI regimen | 1 | 1 |
| Non-TBI containing | 14 | 11 |
| Cyclophosphamide alone | 5 | 7 |
| Busulfan + cyclophosphamide | 5 | 3 |
| Anti-thymocyte globulin | 2 | 0 |
| None | 1† | 0 |
| Other | 1 | 1 |
| GVHD prophylaxis | ||
| Methotrexate only | 8 | 14 |
| Methotrexate + cyclosporine | 8 | 9 |
| Cyclosporine ± prednisone | 6 | 3 |
| Other regimens | 2 | 2 |
| None | 7‡ | 3 |